Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

CSP #2001 - Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (VA Intrepid)

Sponsors

Lead Sponsor: VA Office of Research and Development

Source VA Office of Research and Development
Brief Summary

The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.

Detailed Description

This is a prospective, randomized, double-blind, placebo-controlled, investigation of a six week course of adjunctive rifampin vs. adjunctive matched placebo (riboflavin) added to backbone antibacterial therapy for the treatment of diabetic foot osteomyelitis. Backbone antibacterial therapy will be with single or multiple agents selected by the clinical treatment team based either on culture results or standard empiric therapy, and which can be administered either intravenously or orally. Rifampin will be dosed at 600 mg daily. The primary outcome measure is amputation-free survival. Amputation events include both below- and above-ankle amputations. Primary outcomes will be determined by systematic medical record review and through confirmatory research visits, phone calls and, as needed, information from non-VA providers. The results for amputation-free survival will be analyzed by means of a two-sided log-rank test. The secondary outcomes of complete wound epithelialization and remission of osteomyelitis will be determined by the research team through VA record review and/or direct examination. The study will initially enroll and randomize a total of 880 study participants to receive either rifampin or placebo (riboflavin) in addition to backbone antibiotic therapy prescribed by their clinician. Investigators expect to enroll, on average, close to one subject per month per site (10-12 per year/site) at 28 VA medical centers to achieve total randomization of 880 subjects over three years. In meeting this average site enrollment projection, Investigators anticipate variation in enrollment between larger and smaller sites, and between high-performing and low-performing sites. Subjects will be followed through the end of the second year after randomization or until a study primary endpoint event (amputation or death) occurs. On average, study participants will be followed for 1.8 years through systematic review of medical records, and by study visits and phone calls.

Overall Status Recruiting
Start Date 2018-01-22
Completion Date 2022-01-22
Primary Completion Date 2022-01-22
Phase Phase 4
Study Type Interventional
Primary Outcome
Measure Time Frame
Amputation-Free Survival Assessed 2 years post intervention
Secondary Outcome
Measure Time Frame
Time to Amputation Assessed 2 years post intervention
New course of antibacterial therapy for ipsilateral foot infection Assessed 2 years post intervention
Quality of Life - SF-36 Assessed 12 months post intervention
Ambulatory Status Assessed 12 months post intervention
Incidence of Falls Assessed 12 months post intervention
Incidence of adverse events related to direct toxicity of rifampin Assessed 3 months post intervention
Incidence of adverse events from drug interactions Assessed 3 months post intervention
Comparative dropout Assessed 6 weeks post intervention
Remission of osteomyelitis Assessed at 1 year post intervention
Complete epithelialization of the wound Assessed 1 year post intervention
First occurrence of ipsilateral amputation related to index osteomyelitis Assessed 2 years post intervention
Enrollment 880
Condition
Intervention

Intervention Type: Drug

Intervention Name: Rifampin

Description: Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.

Arm Group Label: Active drug

Intervention Type: Drug

Intervention Name: Riboflavin Placebo

Description: A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.

Arm Group Label: Placebo

Eligibility

Criteria:

Inclusion Criteria: 1. Age 18 and 89 years 2. Diagnosis of diabetes mellitus, either by: 1) use of oral hypoglycemic agents or insulin at the time of enrollment; 2) a hemoglobin A1c (HgA1c) level within the past 90 days > 6.5; or 3) a medical record diagnosis of diabetes mellitus by a clinician on two or more occasions in the previous 10 years 3. Definite or probable osteomyelitis in the diabetic foot, as defined by the International Working Group on the Diabetic Foot (Table 1). Criteria must be present at some point within 90 days prior to enrollment. 4. All planned debridement has been completed prior to randomization. 5. A course of backbone antimicrobial therapy has been selected. Exclusion Criteria: 1. Patient unable to receive enteral medication. 2. Patient is allergic to or intolerant of rifampin. 3. Patient is taking a drug that has interactions with rifampin that would require either stoppage, substitution or an empiric dose modification that may place the patient at medical risk. 4. Within 30 days of enrollment, patient is taking immunosuppressive medications to prevent rejection of an organ transplant or is receiving chemotherapy for cancer or molecularly targeted therapies for cancer. 5. Patient is receiving antiretroviral therapy for HIV or antiviral medication for Hepatitis C. 6. Patient is participating in another interventional clinical trial for which a waiver of dual enrollment with CSP#2001 has not been obtained. 7. Patient has an ALT > 3 times the upper limit of normal for the site laboratory, or total bilirubin > 2.5 times the upper limit of normal for the site laboratory*,***; INR > 1.5, OR patient has Child-Pugh Class C Cirrhosis. 8. Patient has a baseline white blood cell count (WBC) <2000 cells/mm3 OR platelet count <50,000 cells/mm3** OR hemoglobin <8.0 g/dL.**,*** 9. Women of child-bearing potential (those with menses within the last year) with a positive serum pregnancy test. 10. Patient is believed unlikely to be able to complete the trial due to medical conditions. 11. Patient is believed unlikely to complete the trial due to neurologic and psycho-behavioral disorders such as active substance abuse or dependence, disabling dementias or psychoses. 12. Patient refuses or is clinically unable to undergo the recommended level of debridement. 13. Indwelling hardware present in the foot, at the site of the index osteomyelitis. 14. Treatment with antibacterial agents for infection at another site, where the duration of treatment is anticipated to be greater than 14 days. 15. Patient is receiving therapy for COVID-19 that interacts with rifampin. - Patients with total bilirubin > 2 times the ULN who have Gilbert's Disease or any other inherited disease affecting bilirubin metabolism without meeting other exclusionary criteria, may be considered for inclusion in the study. - Patients with platelet count <50,000 cells/mm3 due only to hypersplenism and meeting no other exclusionary criteria may be considered for inclusion in the study. - If multiple laboratory values are available, the most recent value will be applied for eligibility.

Gender:

All

Minimum Age:

18 Years

Maximum Age:

89 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Mary T Bessesen, MD Study Chair Rocky Mountain Regional VA Medical Center, Aurora, CO
Overall Contact

Last Name: Kelly Harrington, PhD

Phone: (617) 232-9500

Email: [email protected]

Location
Facility: Status:
Phoenix VA Health Care System, Phoenix, AZ | Phoenix, Arizona, 85012, United States Active, not recruiting
VA Loma Linda Healthcare System, Loma Linda, CA | Loma Linda, California, 92357, United States Recruiting Ronald Fernando, MD [email protected]
VA Long Beach Healthcare System, Long Beach, CA | Long Beach, California, 90822, United States Recruiting Ian Gordon, MD [email protected]
VA Palo Alto Health Care System, Palo Alto, CA | Palo Alto, California, 94304-1290, United States Active, not recruiting
VA Northern California Health Care System, Mather, CA | Sacramento, California, 95655, United States Recruiting Hien Nguyen, MD [email protected]
VA Greater Los Angeles Healthcare System, West Los Angeles, CA | West Los Angeles, California, 90073, United States Terminated
Rocky Mountain Regional VA Medical Center, Aurora, CO | Aurora, Colorado, 80045, United States Recruiting Mary T Bessesen, MD 303-393-2837 [email protected] Mary T Bessesen, MD Study Chair
Washington DC VA Medical Center, Washington, DC | Washington, District of Columbia, 20422, United States Recruiting Angelike Liappis, MD [email protected]
Bay Pines VA Healthcare System, Pay Pines, FL | Bay Pines, Florida, 33744, United States Recruiting David Johnson, MD [email protected]
North Florida/South Georgia Veterans Health System, Gainesville, FL | Gainesville, Florida, 32608, United States Recruiting Gary Wang, MD [email protected]
Miami VA Healthcare System, Miami, FL | Miami, Florida, 33125, United States Recruiting Stuti Dang, MD [email protected]
James A. Haley Veterans' Hospital, Tampa, FL | Tampa, Florida, 33612, United States Recruiting John Toney, MD [email protected]
Atlanta VA Medical and Rehab Center, Decatur, GA | Decatur, Georgia, 30033, United States Recruiting Luke Brewster, MD [email protected]
VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor, Michigan, 48105, United States Recruiting Carol Kauffman, MD [email protected]
Minneapolis VA Health Care System, Minneapolis, MN | Minneapolis, Minnesota, 55417, United States Recruiting Derrick Green, MD [email protected]
St. Louis VA Medical Center John Cochran Division, St. Louis, MO | Saint Louis, Missouri, 63106, United States Terminated
James J. Peters VA Medical Center, Bronx, NY | Bronx, New York, 10468, United States Recruiting Michael Gelman, MD [email protected]
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC | Salisbury, North Carolina, 28144, United States Active, not recruiting
Cincinnati VA Medical Center, Cincinnati, OH | Cincinnati, Ohio, 45220, United States Recruiting George Smulian, MD [email protected]
Louis Stokes VA Medical Center, Cleveland, OH | Cleveland, Ohio, 44106, United States Recruiting Marion Skalweit, MD [email protected]
Dayton VA Medical Center, Dayton, OH | Dayton, Ohio, 45428, United States Recruiting Hari Polenakovik, MD [email protected]
Oklahoma City VA Medical Center, Oklahoma City, OK | Oklahoma City, Oklahoma, 73104, United States Recruiting George Kurdgelashvili, MD [email protected]
VA Portland Health Care System, Portland, OR | Portland, Oregon, 97239, United States Recruiting Marissa Maier, MD [email protected]
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Nashville, Tennessee, 37212-2637, United States Recruiting Todd Hulgan, MD [email protected]
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX | Dallas, Texas, 75216, United States Recruiting Roger Bedimo, MD [email protected]
Michael E. DeBakey VA Medical Center, Houston, TX | Houston, Texas, 77030, United States Recruiting Neal Barshes, MD [email protected]
South Texas Health Care System, San Antonio, TX | San Antonio, Texas, 78229, United States Recruiting Jose Cadena Zuluaga, MD [email protected]
VA Salt Lake City Health Care System, Salt Lake City, UT | Salt Lake City, Utah, 84148, United States Recruiting Clint Larsen, DPM [email protected]
Salem VA Medical Center, Salem, VA | Salem, Virginia, 24153, United States Recruiting Shikha Vasudeva, MD [email protected]
William S. Middleton Memorial Veterans Hospital, Madison, WI | Madison, Wisconsin, 53705, United States Recruiting Christopher Crnich, MD [email protected]
Location Countries

United States

Verification Date

2021-05-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Active drug

Type: Active Comparator

Description: Patients receive oral adjunctive rifampin therapy

Label: Placebo

Type: Placebo Comparator

Description: Patients receive oral riboflavin

Acronym VA INTREPID
Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Double (Participant, Investigator)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News